|
|
| 7:45 |
Registration and Buffet Breakfast |
| 8:30 |
Welcome and Introductions
|
| 8:45 |
President’s Keynote
Achieving cancer without disease: antiangiogenic therapy for cancer prevention
William W. Li, M.D., The Angiogenesis Foundation
|
Session I: NEW TARGETS & STRATEGIES
| 9:30 |
Novel non-hypoxia mediated mechanisms for tumor angiogenesis
Lynn Hlatky, Ph.D., Tufts University School of Medicine |
| 10:00 |
ALK1-receptor: a novel antiangiogenic and antitumor target
Nicolas Solban, Ph.D., Acceleron Pharma
|
| 10:30 |
MicroRNAs as regulators of angiogenesis
Nathan Lawson, Ph.D., UMASS Medical School
|
| 11:00 |
Break |
| 11:15 |
Angiogenesis Film
Michael Astrachan, XVIVO Scientific Animation |
| 11:30 |
Drug conjugation for improved delivery of angiogenesis inhibitors
Julie A. Olson, Ph.D., Mersana Therapeutics |
| 12:00 |
Expanding delivery of RNAi therapeutics
Tatiana Novobrantseva, Ph.D., Alnylam Pharmaceuticals |
| 12:30 |
Moderated Panel Discussion and Q&A |
| 1:00 |
Networking Luncheon
|
Session II: BIOMARKERS & IMAGING
| 2:15 |
Integrin and other tracers for angiogenesis imaging
Matthew S. Morrison, Ph.D., GE Healthcare
|
| 2:45 |
Clinical markers of antiangiogenic therapy in platelet proteome
Giannoula Klement, M.D., FRCPC, Tufts Medical Center |
| 3:15 |
Endothelial progenitor cells as systemic sensors of breast cancer
Raj Tiwari, Ph.D., New York Medical College
|
| 3:45 |
Biomarker identification in antiangiogenesis cancer trials
Peter Wilson, Ph.D., Keck School of Medicine of USC
|
| 4:15 |
Moderated Panel Discussion and Q&A |
| 5:00 |
Cocktail Reception & Networking
|
| 7:45 |
Registration and Buffet Breakfast |
| 8:15 |
Summary of Day 1 and Opening Remarks
|
Session III: TRENDS IN ANGIOPREVENTION
| 8:30 |
Chemoprevention of esophagus and colon cancer with berries: antiangiogenic actions
Gary D. Stoner, Ph.D., Ohio State University |
| 9:00 |
Omega 3 PUFAs in angiogenesis
Jing Chen, Ph.D., Children’s Hospital Boston |
| 9:30 |
Dietary impact on cancer epigenetics and angiogenesis
Nancy Emenaker, Ph.D., RD, National Cancer Institute
|
| 10:00 |
Moderated Panel Discussion and Q&A |
| 10:15 |
Break |
| 10:30 |
Bob Paul
Metastatic Cancer Survivor |
Session IV: CLINICAL DEVELOPMENT
| 10:45 |
Special Health Policy Lecture: The beginning of a new era - guidance for comparative effectiveness and patient centered outcomes for oncology innovation
Kenneth R. Carson, M.D., Washington University School of Medicine
|
| 11:15 |
Special Health Policy Lecture: Health policy issues in targeted oncology
Brian P. Carey, JD, Foley Hoag LLP |
| 11:45 |
Controversies on anti-VEGF therapy for breast cancer
Erica Mayer, M.D., Dana Farber Cancer Institute
|
| 12:15 |
Moderated Panel Discussion and Q&A |
| 12:30 |
Networking Luncheon |
| 1:45 |
Antiangiogenic therapy response versus pseudo-response in brain cancer
A. Gregory Sorensen, M.D., Massachusetts General Hospital
|
| 2:15 |
Next generation antiangiogenic strategies for renal cell carcinoma
Michael B. Atkins, M.D., Beth Israel Deaconness Medical Center |
| 2:45 |
Integrin-targeting for advanced malignancies
David A. Reardon, M.D., Duke University |
| 3:15 |
Sequential angiogenic blockade for the treatment of recurrent cancer
Joyce F. Liu, M.D., Dana Farber Cancer Institute |
| 3:45 |
Moderated Panel Discussion and Q&A |
| 4:00 |
Break |
| 4:15 |
Young Investigator’s Session: Selected Presentations
CADASIL pathophysiology in mice and humans with hypomorphic Notch 3 mutations
Joseph Arboleda, Ph.D., Schepens Eye Research Institute
Antiangiogenic and Anti-Invasive Effects of Proton Irradiation
Swati Girdhani, Ph.D., Tufts University School of Medicine
The receptor tyrosine kinase Axl mediates VEGF/VEGFR-2-induced PI3K/Akt activation in endothelial cell
Guoxiang Ruan, Ph.D., Schepens Eye Research Institute |
| 5:30 |
Closing Remarks & Close of Conference |
|
| |
|
| |
REGISTRATION
You will receive an email confirmation
of your registration after payment.
Registration fees
for the 2-day conference.
Industry $549
|
Clinical/Academic $249
|
Student $99
|
|
|
Program Description